376
Views
6
CrossRef citations to date
0
Altmetric
Reviews

The impact of menopausal hormone therapy on overall mortality – a comprehensive review

ORCID Icon, &
Pages 447-459 | Received 20 Dec 2019, Accepted 05 May 2020, Published online: 18 Jun 2020

References

  • Gartlehner G, Patel SV, Feltner C, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force. JAMA 2017;318:2234–49
  • Alexandersen P, Tanko LB, Bagger YZ, Qin G, Christiansen C. The long-term impact of 2–3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 2006;9:108–18
  • Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
  • Cauley JA, Seeley DG, Browner WS, et al. Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures. Arch Intern Med 1997;157:2181–7
  • Chen L, Mishra GD, Dobson AJ, Wilson LF, Jones MA. Protective effect of hormone therapy among women with hysterectomy/oophorectomy. Hum Reprod 2017;32:885–92
  • Ettinger B, Friedman GD, Bush T, Quesenberry CP. Jr., Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6–12
  • Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128–32
  • Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769–75
  • Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036–45
  • Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–8
  • Holm M, Olsen A, Au Yeung SL, et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG 2018;126:55–63
  • Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987;94:620–35
  • Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080–6
  • LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
  • Lokkegaard E, Pedersen AT, Heitmann BL, et al. Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study. BMJ 2003;326:426
  • Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
  • Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials. JAMA 2017;318:927–38
  • Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 2015;22:976–83
  • Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9
  • Paganini-Hill A, Corrada MM, Kawas CH. Increased longevity in older users of postmenopausal estrogen therapy: the leisure world cohort study. Menopause 2006;13:12–18
  • Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Health outcomes associated with hormone therapy in Australian women. Curr Drug Saf 2009;4:169–72
  • Pentti K, Honkanen R, Tuppurainen MT, Sandini L, KröGer H, Saarikoski S. Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio osteoporosis risk factor and prevention study. Eur J Endocrinol 2006;154:101–7
  • Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12–23
  • Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
  • Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
  • Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409
  • Sourander L, Rajala T, Räihä I, Mäkinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998;352:1965–9
  • Stram DO, Liu Y, Henderson KD, et al. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 2011;18:253–61
  • Symer MM, Wong NZ, Abelson JS, Milsom JW, Yeo HL. Hormone replacement therapy and colorectal cancer incidence and mortality in the prostate, lung, colorectal, and ovarian cancer screening trial. Clin Colorectal Cancer 2018;17:e281–e8
  • Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239
  • Vickers MR, Martin J, Meade TW, Team W. The Women’s international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health 2007;7:2
  • Cooper GS, Baird DD, Weinberg CR, Ephross SA, Sandler DP. Age at menopause and childbearing patterns in relation to mortality. Am J Epidemiol 2000;151:620–3
  • Benkhadra K, Mohammed K, Al Nofal A, et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:4021–8
  • Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016–22 e1
  • Williamson PR, Altman DG, Bagley H, et al. The COMET handbook: version 1.0. Trials 2017;18:280
  • Hickey, M. COMMA (Core Outcomes in Menopause): International collaboration to measure core outcomes in menopause. 2016. Available from: http://www.comet-initiative.org/studies/details/917.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.